Study: Vioxx poses even short-term risks

May 3, 2006

A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.

The study, published Tuesday in the Canadian Medical Association Journal, said people 65 and older are at the greatest risk of suffering a heart attack within 6-13 days of their first ingestion of Vioxx.

The McGill University study also found elderly patients' heart attack risk did not increase the longer they took the drug, which Merck pulled off the world market in 2004.

A key element of Merck's defense has been that it took 18 months or longer for the heart attack risk to increase, The Wall Street Journal reported.

Reacting to the study, Merck said its strategy was unchanged "and we continue to believe those (short-term) cases have no merit," said lawyer Ted Mayer.

However, plaintiffs' lawyer Andy Birchfield said the study "strengthens our hand tremendously."

"From the very beginning, we have said it doesn't take 18 months," Birchfield said.

Copyright 2006 by United Press International

Explore further: Merck will pay $950M to settle Vioxx investigation

Related Stories

FDA backs Vytorin for kidney disease patients

October 31, 2011

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

Merck blood thinner shows mixed results: study

March 24, 2012

An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

Study raises new questions about Merck pill Zetia

November 16, 2009

(AP) -- A new study raises fresh concerns about Zetia and its cousin, Vytorin - drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work.

Merck continuing study of cholesterol drug in new class

November 13, 2015

Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent ...

Recommended for you

Milky way had a blowout bash six million years ago

August 29, 2016

The center of the Milky Way galaxy is currently a quiet place where a supermassive black hole slumbers, only occasionally slurping small sips of hydrogen gas. But it wasn't always this way. A new study shows that 6 million ...

The Anthropocene is here: scientists

August 29, 2016

The human impact on Earth's chemistry and climate has cut short the 11,700-year-old geological epoch known as the Holocene and ushered in a new one, scientists said Monday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.